Workflow
最新资金净流入超2000万元，恒生医疗ETF嘉实(159557)上涨1.48%，规模创近1年新高！
Sou Hu Cai Jing·2025-07-03 02:53

Core Viewpoint - The Hang Seng Healthcare Index has shown strong performance, with significant increases in constituent stocks, indicating a positive trend in the healthcare sector [1][2]. Group 1: Market Performance - As of July 3, 2025, the Hang Seng Healthcare Index rose by 1.67%, with notable gains from stocks such as Huahao Zhongtian Pharmaceutical-B (+16.97%) and Ascentage Pharma-B (+7.11%) [1]. - The Hang Seng Healthcare ETF (Jia Shi, 159557) increased by 1.48% [1]. - The ETF recorded a turnover of 6.64% and a transaction volume of 21.35 million yuan, with an average daily transaction volume of 46.55 million yuan over the past month [2]. Group 2: Fund Performance - The latest scale of the Hang Seng Healthcare ETF reached 315 million yuan, marking a one-year high, with the latest share count at 221 million, also a three-month high [2]. - The ETF has seen a net inflow of 2.048 million yuan recently [2]. - Over the past year, the net value of the ETF has increased by 68.77%, ranking 16th out of 122 QDII equity funds, placing it in the top 13.11% [2]. Group 3: Valuation Metrics - The current price-to-earnings ratio (PE-TTM) of the Hang Seng Healthcare Index is 27.19, which is in the 9.23rd percentile over the past three years, indicating a valuation lower than 90.77% of the historical data [2]. Group 4: Sector Composition - The top ten weighted stocks in the Hang Seng Healthcare Index account for 57.72% of the index, including companies like Innovent Biologics, BeiGene, and WuXi Biologics [3][5]. - The top stocks have shown varied performance, with notable increases in companies like XinDa Biologics (+6.12%) and Kangfang Biologics (+6.95%) [5]. Group 5: Industry Outlook - According to Xiangcai Securities, the domestic innovative drug industry is expected to reach a turning point in 2025, shifting from capital-driven to profit-driven growth, presenting opportunities for both performance and valuation recovery [6]. - The commercialization of innovative products and the acceleration of research outcomes are expected to support market recovery [6].